Recent studies have shown that the use of cytokines such as granulocyte colony-stimulating factor (G-CSF) to ameliorate chemotherapy-induced myelosuppression may enhance the viability of tumour cells with functional receptors for these cytokines. In this study, therefore, we used murine bone marrow (BM) cells in an in vitro model in an attempt to determine whether topoisomerase inhibitors (camptothecin, etoposide and doxorubicin) induce myelosuppression (BM cell death) and whether novel treatments other than the administration of G-CSF can be used for rescue from myelosuppression. DNA fragmentation assay, ultrasuctural analysis and cell cycle analysis demonstrated that these chemotherapeutic agents induced apoptosis in BM cells. We demonstrated in addition that enforced expression of the bcl-2 gene in BM cells by MPZenNeo (bcl-2) retroviral gene transfer increased resistance to the apoptosis induced by these agents. Thes findings suggest the possibility that enforced expression of the bdl-2 gene in BM cells using gene transfer techniques may enable rescue from chemotherapy-induced myelosuppression.
The intensive use of chemotherapeutic agents is a mainstay in the current treatment of malignant diseases. However, myelosuppression is a common and serious complication of treatment with these agents since most lack specificity for malignant cells. Therefore, reduction in the degree of duration of chemotherapy-induced myelosuppression may decrease the morbidity of chemotherapy and enhance tumour control.
In general, rhG-CSF is well tolerated within a range of doses effective in increasing the rate of myeloid recovery after high-dose chemotherapy (Antman et al., 1988; Brandt et al., 1988) . However, Lotem and Sachs (1992) have recently suggested that the use of cytokines such as G-CSF to ameliorate myelosuppression that follows the use of chemotherapeutic agents or radiation in cancer therapy may not only stimulate the recovery of normal hematopoietic cells but also enhance the viability of leukaemic cells or non-haematopoietic tumour cells with functional receptors for these cytokines. Therefore, in the case of tumours with G-CSF receptors, the application of novel treatments other than the administration of rhGM-CSF will be necessary for amelioration of the myelosuppression induced by chemotherapy.
While much information is available on the cellular targets and mechanisms of action of chemotherapeutic agents, little is known about how they actually induce cell death. Recent studies have shown that the most likely mechanism of cell death following exposure to chemotherapeutic agents is apoptosis (programmed cell death) (Eastman, 1990; Martin et al., 1990; Sorenson et al., 1990; Martin & Cotter, 1991; Walker et al., 1991; Onishi et al., 1993) . Therefore, apoptosis of bone marrow (BM) cells may be the main mechanism of myelosuppression.
Drugs that interact with DNA topoisomerase, such as CPT, VP-16 and doxorubicin, have been found to be particularly useful in chemotherapeutic treatment, but do tend to induce myelosuppression (Glisson & Ross, 1987; Kohn et al., 1987; Zwelling, 1989) . Recently, CPT and VP-16 have been
shown to induce apoptosis with DNA cleavage in thymocytes (Walker et al., 1991; Onishi et al., 1993) and in concanavalin A-stimulated splenocytes (Jaxel et al., 1988) . In addition, doxorubicin is known to induce apoptosis in the murine small intestinal tract (Thakkar & Potten, 1992) and in thymocytes (Onishi et al., 1993) . In this study, therefore, we used DNA fragmentation assay, ultrastructual analysis and cell cycle analysis in attempting to determine whether CPT, and doxorubicin induce apoptosis in murine BM cells.
On the other hand, forced expression of bcl-2, a gene implicated in the genesis of follicular lymphoma (Tsujimoto et al., 1984; Bakhshi et al., 1985; Cleary & Sklar, 1986) , has been shown to prevent apoptosis of factor-dependent myeloid cells and pro-B-cell lines cultured in the absence of growth factor (Cleary & Sklar, 1985; Vaux et al., 1988) . In addition, expression of bcl-2 has been shown to increase the resistance of cells to ethanol, methotrexate and heat shock (Nunez et al., 1990) . We therefore wished to determine whether the bcl-2 gene could prevent BM cell death induced by chemotherapeutic agents. Accordingly, we introduced a human bcl-2 gene into BM cells by MPZenNeo (bcl-2) retroviral gene transfer (Cleary & Sklar, 1985; Tsujimoto, 1989) .
In this study, we also attempted to determine whether a high rate of expression of the bcl-2 gene in BM cells can prevent cell death induced by chemotherapy.
Materiak and methods

Bone marrow cells
Murine bone marrow (BM) cells were obtained from the femurs of 5-to 6-week-old Balb/c female mice. Marrow plugs were flushed out with phosphate-buffered saline (PBS), passaged through a 23 gauge needle, washed and resuspended in complete RPMI-1640 medium supplemented with 10% heatinactivated fetal calf serum (FCS) (Gibco, Grand Island, NY, USA), 4 mM glutamine, 50 U mld I penicilln and 50;Lg ml 1I streptomycin at a density of 106 cells ml1'. Macrophages and other adherent cells were removed after an 18 h period of incubation at 37C in 5% carbon dioxide in tissue culture flasks as previously described (Strassman et al., 1988) . Nonadherent cells were collected and resuspended in complete medium and cultured with 1Ong ml1 rhG-CSF kindly supplied by Chugai Pharmaceuticals (Tokyo, Japan).
Chemotherapeutic agents CPT was purchased from Sigma (St Louis, MO, USA). VP-16 was a generous gift from Nippon Kayaku (Tokyo, Japan). These agents were obtained in powder form, from which 3.5mgml-' or l0mgml-' stock solution was prepared in dimethylsulphoxide. Doxorubicin was a generous gift from Kyowa Hakko Kogyo (Tokyo). It was also obtained in powder form, from which a 1.0mg ml' stock solution was prepared in normal saline.
Retroviru infection
A 942 bp blunted (EcoRIITaqI cDNA fragment containing the entire human bcl-2 coding sequence (Tsujimoto, 1989) was inserted into the blunted XhoI site of the retroviral vector MPZenSVNeo, allowing expression of bcl-2 from the MPSV long terminal repeat (Cleary & Sklar, 1985; Hariharan et al., 1988) . Murine fibroblast lnes secreting or MPZenNeo virus free of helper virus were obtained by electroporating the *2 packaging line (Mann et al., 1983) with retroviral plasmid DNA. BM cells were infected by adding the filtered superatant of the virus-producing *2 fibroblast cells with incubation for 24h. Infected BM cells were seected in 800pgml'l G418. The production of the bcl-2 gene in BM cells was asd by immunoprecipitation using anti-human Bcl-2 MAb (Biochemicals, Tokyo, Japan).
Immwnoprecipitation BM cells were washed with methionine-free medium containing 5% FCS, suspended at 2.5 x 10' cells ml-1 in the same medium supplemented with 250 LCi ml' [35SpL-methionine (Amersham, Arlington Heights, IL, USA) and cultivated for 5 h. The cells were harvested, washed with PBS and lysed as previously described (Kondo et al., 1992) . The lysate was mixed with anti-human Bcl-2 MAb, and the immune complexes were precipitated with protein A-Sepharose (Amersham) and analysed on a 12% sodium dodecyl sulphate-polyacrylamide gel.
Cell viability asays BM cells were seeded at 10' cells per well (1.0 ml) in 24-well plates and treated with various chemotherapeutic agents at clinically reklvant concentrations. Each day an aliquot was examined microscopially using trypan blue to determine percentage cell viability.
Inhibition of RNA and protein synthesis To determine whether inhibition of RNA or protein synthesis results in inhibition of the cytotoxcity induced by chemotherapeutic agents, BM cells were pretreated for 15 min with actinomycin D (80 ng ml-') or cycloheximide (0.7 jAg ml-') prior to chemotherapy. Higher concentrations of actinomycin D and cycloheximide caused cytotoxcity in BM cells by themselves. Changes in cytotoxcity were determined by trypan blue exclusion.
Analysis of DNA fragmentation in agarose gel
This assay was performed as previously decibed (Ishida et al., 1992) . Brifly, harvested BM cells (I x 10') were centrifuged and washed twice with cold PBS. The cell pdet was lysed in l.Oml of a buffer consisting of IOmm Tris-HCL 10 mM EDTA and 0.2% Triton X-100 (pH 7.5). After 10 min on ice, the lysate was centrifiged (13,000 g) for 10 min at 4C in an Eppendorf microfuge. Tben, the supernatant (containing RNA and fragmented DNA, but not intact chromatin) was extacted first with phenol and then with phenol-chioroform:isoamyl alcohol (24:1). The aqueous phase was made to 300 mM sodium chloride and nuceic acids were precipitated with two vohlm of ethanol. The pelet was rinsed with 70% ethanol, air dried and dissolved in 20 p1 of 1Omm
Tris-HC-1 mM EDTA (pH 7.5). Following digestion of RNA with RNAse A (0.6 mg ml-', at 37C for 30min), the sample was electrophoresed in a 2% agarose gel with Boyer's buffer (50 mM 20 Resaks BM cell viability When assayed 7 days after adding 3.5 jg ml-' CPIT, lOagml-' VP-16 or lOjgml'-doxorubicin to cultures, parental BM cells were nearly all dead (Figure 1 ). In contrast, the survival of BM cells cultured in the presence of actinomycin D or cycloheximide was maintained at > 50% for at least 7 days. These results indicate the loss of BM cell viability induced by CPI, VP-16 or doxorubicin is almost dependent on RNA and protein synthesis. To determine whether Bc-2 prevents loss of viability induced by these agents, we infected BM cls with a retrovis bearing genes for both Bcl-2 and G418 resistance or a control virus bearing the gene for G418 resistance alone. Expression of the introduced bdl-2 gene was confirmed by immunoprecipitation using anti-human Bcl-2 MAb (Figure 2) , and the expression of Bcl-2 protein was maintained for at kast 1 month (data not shown). On the other hand, endogenous expression of Bcl-2 in parental BM cells was not d d by this MAb (Figure 2 ). This MAb does not pick up mouse Bcl-2 protein according to the manufacturer's protocoL but mature polymorphonuclear BM cells are shown to be essentally negative for Bc-2 epression (Hockenbery et al., 1991) . Tbherore, we suggest that endogeous ecpression of Bcl-2 in BM cells may be very less than exogenous expresson and not infuee our rult. In addition, subdoning was un ry to achieve BM cells with high lvls of bcl-2 expression because the gene transfer ecncy was high (positive cells>90%, determined by an indirect mmunofluoresnce meod using anti-human Bcl-2 MAb), and transfected BM cells showed the alnost same kvel of bcl-2 expression (data not shown). About 75% of b-2-expressing BM cells exposed to chemotherapeutic agents i viable after 7 days (Figure 1 ). In contrast, BM cells expressig No alone lost viability to the same extent as did the uninfected, parental BM cells. These findings demonstrate that enforced expression of bcl-2 increased the istance of BM cells to chemotherapeutic agents DNA fragmentation DNA fragmentation in BM cells exposed to 3.5 jg ml-' CPT, 10 jg ml-' VP-16 or 10 jg ml-' doxorubicin for 48 h at 3TC was determined. Figure 3 shows that the DNA of bcl-2-expressng BM cells was intact, whereas that of uninfected BM cells and those expressing Neo alone was bcl-2 RESCUES MYELOSLPPRESSION 423 broken into nucleosome-sized fragments. These results demonstrate that the expression of bcl-2 gene was nearly sufficient to maintain the integrity of DNA in BM cells treated with chemotherapeutic agents. I viability of bcl-2-expressing BM cells remained high. However, about 20% of bcl-2-expressing BM cells were also dead; the mechanism of cell death was apoptosis (data not shown).
Cell cycle
We examined the changes in the intensity of fluorescence of DNA using flow cytometry. As shown in Figure 5 Nuclear enzymes, in particular DNA topoisomerases, function in cellular proliferation and differentiation by inducing changes in the topology of DNA, enabling DNA synthesis, recombination and transcription (Wang, 1985; Liu, 1989 (Adriamycin) have been thought to exert effects via interaction with topoisomerase II. However, the exact mechanism by which interaction of these agents with the topoisomerase I or 11-DNA cleavable complex leads to cell death is unclear. In this study, we show that topoisomerase inhibitors induce apoptosis in BM cells in the presence of new RNA and protein synthesis. This active process, apoptosis of BM cells, may be the main mechanism of drug-induced myelosuppression, since the nadir of peripheral neutrophils occurred usually on days 7-10 post treatment of VP-16 and doxorubicin (Wakui et al., 1986; Bronchud et al., 1989 (Telford et al., 1991; Walker et al., 1991; Del Bino et al., 1992 bcl-2 RESCUES MYELOSUPPRESSION chromosome segregation at mitosis since these are two cellular processes that have an absolute requirement for the enzyme (Walker et al.. 1991) . This cytotoxicity has been shown to correlate with drug-induced DNA cleavage and to increase when the drugs are administered during these phases of the cell cycle (Long & Stringfellow, 1988 (Tsujimoto et al., 1987; Chen-Levy et al., 1989 ) that appears to be associated with the inner membrane of the mitochondria (Hockenbery et al., 1990) . Insight into the biological function of Bcl-2 came with the discovery that enforced bc1-2 expression delays the death of certain haematopoietic cell lines deprived of growth factor (Cleary & Sklar, 1985) . However, the mechanism by which the bcl-2 gene regulates cell viability remains unclear, since the predicted amino acid sequence of the protein it codes for bears no significant homology to other known proteins and no biochemical activity has yet been ascribed to it (Miyashita & Reed, 1992 (McDonnell et al., 1990; Strasser et al.. 1991) , and Bcl-2 confers survival advantage on Epstein-Barr virus-infected B cells (Nunez et al., 1990; Henderson et al., 1991 Reed (1992. 1993) , who have recently demonstrated that bcl-2 gene transfer increases the relative resistance or murine lymphoid cells and human leukaemia cells to cell death and DNA fragmentation induced by chemotherapeutic drugs such as methotrexate, vincristine (Miyashita & Reed, 1992) and VP-16 (Miyashita & Reed, 1993) . The bcl-2 gene might therefore interfere with a final common pathway for cell death that can be activated by multiple mechanisms.
In conclusion, our findings suggest the possibility that enforced expression of the bcl-2 gene in BM cells using gene transfer techniques may enable rescue from myelosuppression (BM cell death) induced by chemotherapeutic agents such as topoisomerase inhibitors. We are at present attempting to determine whether the bcl-2 gene can be used to rescue chemotherapy-induced myelosuppression in an in vivo model. without inhibiting the cytotoxic effect of agents on tumour cells.
Abbreviadoas rhG-CSF. recombinant human granulocy-te colony-stimulating factor; CPT. camptothecin; MAb. monoclonal antibody.
